ReviewInternational ophthalmology2021
New perspectives in keratoconus treatment: an update on iontophoresis-assisted corneal collagen crosslinking.
Review in International ophthalmology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 26 citations in OpenAlex.
- Nanomaterial-Enhanced Corneal Cross-Linking: Engineering Strategies for Transforming Keratoconus Management.Pharmaceutics · 2026Review
- Advancements and Innovations in Keratoconus Management: A Review of Current Practices.Journal of clinical medicine · 2025Review
- Oxygen-releasing microneedles enhance the therapeutic effect of corneal ectasia by increasing corneal oxygen content and riboflavin concentration during cross-linking.Materials today. Bio · 2025Article
- A Review of Keratoconus Cross-Linking Treatment Methods.Journal of clinical medicine · 2025Review
- Epi-off riboflavin with vitamin E TPGS (Ribocross®) cross-linking: one-year outcome.International ophthalmology · 2024Article
- Analysis of the effect of calcium ions on promoting the penetrability of riboflavin into the corneal stroma by iontophoresis.International ophthalmology · 2024Article
- Corneal collagen cross-linking in patients with keratoconus from the Dresden protocol to customized solutions: theoretical basis.International journal of ophthalmology · 2024Review
- "Outcomes of Iontophoresis Cross-Linking in Asymmetric Keratoconus: A Retrospective Analysis of High Visual Acuity Eyes Under 25 Years Old".Clinical ophthalmology (Auckland, N.Z.) · 2024Article
- Application of iontophoresis in ophthalmic practice: an innovative strategy to deliver drugs into the eye.Drug delivery · 2023Review
- A review of the epithelial and stromal effects of corneal collagen crosslinking.The ocular surface · 2023Review
- Corneal cross-linking in patients with keratoconus: up to 13 years of follow-up.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2023Article
- [Treatment indications for corneal crosslinking and clinical results of new corneal crosslinking techniques].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2022Review
- [Principles of corneal cross-linking : Presentation based on the development of the various treatment protocols].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Keratoconus is a bilateral, asymmetric and progressive corneal disease. It usually results in apical thinning and steepening with corneal deformation and impaired vision. Since the early 1990 s, corneal collagen crosslinking (CXL) has remained the primary treatment to stabilize the progression of the disease. Iontophoresis-assisted CXL (I-CXL) has been proposed as a non-invasive alternative to standard epithelium-off technique, showing promising results. In this article, we review up to date literature to provide state of art knowledge and future perspectives of I-CXL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.